We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Keywords » FDAnews Drug Daily Bulletin

Items Tagged with 'FDAnews Drug Daily Bulletin'

ARTICLES

Wyeth to Answer FDA Reinspection Findings in Guayama Facility

April 13, 2007

Wyeth will respond this month to Form 483 observations from an FDA reinspection of the company's Guayama, Puerto Rico, manufacturing facility, the firm announced.

Read More

Grassley Requests Zyprexa Marketing Documents

April 13, 2007

As part of a Senate Finance Committee investigation, Sen. Chuck Grassley (R-Iowa) is requesting information from Eli Lilly regarding the marketing of its antipsychotic drug Zyprexa.

Read More

Kennedy Introduces PDUFA Reauthorization; Bill Alters Pediatric Exclusivity

April 13, 2007

Sen. Edward Kennedy (D-Mass.) introduced the Prescription Drug User Fee Act (PDUFA) reauthorization last week, proposing a new structure that would increase the agency's user fees by more than $100 million.

Read More

Supreme Court Rejects Generic Lipitor Case

April 12, 2007

The U.S. Supreme Court will not make a determination on Ranbaxy's challenge of the validity and enforceability of Pfizer's main Lipitor patent, the courtsaid last week.

Read More

Analysis Finds Lower Heart Risk With Hormone Therapy for Women in Their 50s

April 12, 2007

A new analysis of previously conducted studies showed no increase in coronary heart disease for women in their 50s who take hormone therapies close the start of menopause, according to an article in The Journal of the American Medical Association (JAMA).

Read More

GSK Warns of Label Tampering on HIV Medications

April 12, 2007

A third party tampered with the labels on two GlaxoSmithKline (GSK) HIV infection medications, placing incorrect and counterfeit labels on the products, the company and the FDA announced.

Read More

Updated FDA Manual Instructs Inspectors to Cite Firms for Not Submitting AERS Reports

April 11, 2007

The FDA added noncompliance with regulations covering submissions of postmarketing adverse event drug reports to the list of reportable Form 483 observations that should be cited during FDA inspections, according to the 2007 Investigations Operations Manual (IOM).

Read More

Purdue Pharma Settles Generic OxyContin Suit Against Impax

April 11, 2007

Impax Laboratories has acknowledged the validity and enforceability of a key patent held by Purdue covering its pain treatment OxyContin, according to a settlement agreement reached by both companies.

Read More

FDA Advisory Committee to Review Merck's Arcoxia

April 11, 2007

An increased risk of side effects from Merck's potential Vioxx successor Arcoxia indicates the drug should not be approved unless it fills an unmet need, an FDA employee told an advisory committee.

Read More

Roche Adds Antibody Discovery Platform With THP Acquisition

April 10, 2007

Roche expanded its preclinical drug-discovery platforms with a $56.5 million acquisition of Therapeutic Human Polyclonals (THP), the firm said.

Read More
More Articles Tagged with 'FDAnews Drug Daily Bulletin'

Upcoming Events

  • 05Dec

    Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

  • 07Dec

    Proactive Supplier Management Using Quality Agreements

  • 13Dec

    FDA Inspection Overhaul: How Things Have Changed in 2023

  • 14Apr

    MAGI 2024: The Clinical Research Conference

Featured Products

  • FDA, FTC and DOJ Enforcement of Medical Device Regulations

    FDA, FTC and DOJ Enforcement of Medical Device Regulations

  • Using Real-World Evidence in Drug and Device Submissions

    Using Real-World Evidence in Drug and Device Submissions

Featured Stories

  • T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

  • Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

  • Novo Nordisk Battles Wegovy/Ozempic Pretenders and Faces Mounjaro’s Superior Study Results

  • Social, Emotional Risks Associated With Multi-Cancer Screening Discussed by Adcomm

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing